Arbutus Biopharma Corp
NASDAQ:ABUS
Arbutus Biopharma Corp
Other Items
Arbutus Biopharma Corp
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Other Items
$30.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.9B
|
CAGR 3-Years
-108%
|
CAGR 5-Years
31%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
13%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$1.1B
|
CAGR 3-Years
-111%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
See Also
What is Arbutus Biopharma Corp's Other Items?
Other Items
30.4m
USD
Based on the financial report for Sep 30, 2025, Arbutus Biopharma Corp's Other Items amounts to 30.4m USD.
What is Arbutus Biopharma Corp's Other Items growth rate?
Other Items CAGR 10Y
10%
Over the last year, the Other Items growth was -4%.
